Pediatric developmental therapies: Interesting new drugs now in early-stage clinical trials

Current Oncology Reports

Volumn 10, Issue 6, 2008, Pages 477-490

  Macy, Margaret E ^a   Sawczyn, Kelly K ^a   Garrington, Timothy P ^a   Graham, Douglas K ^a   Gore, Lia ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALEMTUZUMAB; BEVACIZUMAB; BORTEZOMIB; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; FORODESINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMATINIB; IRINOTECAN; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NELARABINE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; RAPAMYCIN; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; TOSITUMOMAB; UNINDEXED DRUG; VALPROIC ACID; VASCULOTROPIN INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER RELAPSE; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMONOCYTIC LEUKEMIA; NEUROBLASTOMA; REVIEW; SARCOMA; SOLID TUMOR; T CELL LYMPHOMA; TUMOR XENOGRAFT;

EID: 58649109966     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0073-0     Document Type: Review

References (140)

1. HeLon M: Deaths: leading causes for 2004. In National Vital Statistics Reports, vol 56, no 5. Hyattsville, MD: National Center for Health Statistics; 2007.
2. Eapen M, Raetz E, Zhang MJ, et al.: Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: A collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006, 107: 4961-4967.
3. Gaynon PS, Harris RE, Altman AJ, et al.: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 2006, 24: 3150-3156.
4. Nemecek ER, Gooley TA, Woolfrey AE, et al.: Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 2004, 34: 799-806.
5. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS: Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005, 23: 4354-4362.
6. Ceschel S, Casotto V, Valsecchi MG, et al.: Survival after relapse in children with solid tumors: A follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer 2006, 47: 560-566.
7. Crompton BD, Goldsby RE, Weinberg VK, et al.: Survival after recurrence of osteosarcoma: A 20-year experience at a single institution. Pediatr Blood Cancer 2006, 47: 255-259.
8. Gaynon PS, Crotty ML, Sather HN, et al.: Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: A Children's Cancer Group initiative. Leuk Lymphoma 1997, 26: 57-65.
9. Schlieben S, Borkhardt A, Reinisch I, et al.: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996, 10: 957-963.
10. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al.: Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998, 91: 1700-1705.
11. Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997, 15: 2333-2342.
12. Schindler T, Bornmann W, Pellicena P, et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289: 1938-1942.
13. Schultz KR, Bowman WP, Slayton W, et al.: Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children's Oncology Group (COG) Study AALL0031. ASH Annual Meeting Abstracts 2007, 110: 9a.
14. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4: 470.
15. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13: 513-609.
16. Matsunaga T, Shirasawa H, Tanabe M, et al.: Expression of neuronal src mRNA as a favorable marker and inverse correlation to N-myc gene amplification in human neuroblastomas. Int J Cancer 1994, 58: 793-798.
17. Diaz-Montero CM, Wygant JN, McIntyre BW: PI3-K/Aktmediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 2006, 42: 1491-1500.
18. Li S: Src kinase signaling in leukaemia. Int J Biochem Cell Biol 2007, 39: 1483-1488.
19. Ozawa Y, Williams AH, Estes ML, et al.: Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008, 32: 893-903.
20. Spreafico A, Schenone S, Serchi T, et al.: Antiproliferative and proapoptotic activities of new pyrazolo[3juvy4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008, 22: 1560-1571.
21. Shor AC, Keschman EA, Lee FY, et al.: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 2007, 67: 2800-2808.
22. Kolb EA, Gorlick R, Houghton PJ, et al.: Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50: 1198-1206.
23. Armstrong SA, Mabon ME, Silverman LB, et al.: FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004, 103: 3544-3546.
24. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100: 1532-1542.
25. Meshinchi S, Stirewalt DL, Alonzo TA, et al.: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003, 102: 1474-1479.
26. Zwaan CM, Meshinchi S, Radich JP, et al.: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance. Blood 2003, 102: 2387-2394.
27. Levis M, Allebach J, Tse KF, et al.: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99: 3885-3891.
28. O'Farrell AM, Abrams TJ, Yuen HA, et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101: 3597-3605.
29. Smith BD, Levis M, Beran M, et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103: 3669-3676.
30. Weisberg E, Boulton C, Kelly LM, et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1: 433-443.
31. Brown P, Levis M, McIntyre E, et al.: Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 2006, 20: 1368-1376.
32. Shimada A, Hirato J, Kuroiwa M, et al.: Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr Blood Cancer 2008, 50: 213-217.
33. Timeus F, Ricotti E, Crescenzio N, et al.: Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. Lab Invest 2001, 81: 1025-1037.
34. Maris J, Minturn J, Evans A, et al.: Phase I Trial of the Orally Bioavailable TRK Tyrosine Kinase Inhibitor CEP-701 in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study. In SIOP XXXVII Annual Conference. Vancouver, Canada: 2005:416.
35. Goemans BF, Zwaan CM, Miller M, et al.: Mutations in KIT and RAS are frequent events in pediatric corebinding factor acute myeloid leukemia. Leukemia 2005, 19: 1536-1542.
36. Uckan D, Hicsonmez G, Yetgin S, et al.: CD34/CD117 co-expression in childhood acute leukemia. Leuk Res 2000, 24: 201-206.
37. Entz-Werle N, Gaub MP, Lavaux T, et al.: KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target? Int J Cancer 2007, 120: 2510-2516.
38. Do I, Araujo ES, Kalil RK, Bacchini P, et al.: Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol Res Pract 2007, 203: 127-134.
39. Uccini S, Mannarino O, McDowell HP, et al.: Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res 2005, 11: 380-389.
40. Smithey BE, Pappo AS, Hill DA: C-kit expression in pediatric solid tumors: A comparative immunohistochemical study. Am J Surg Pathol 2002, 26: 486-492.
41. Bond M, Bernstein ML, Pappo A, et al.: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2008, 50: 254-258.
42. Growney JD, Clark JJ, Adelsperger J, et al.: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106: 721-724.
43. Schittenhelm MM, Shiraga S, Schroeder A, et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66: 473-481.
44. Burstein HJ, Elias AD, Rugo HS, et al.: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26: 1810-1816.
45. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25: 1539-1544.
46. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23: 2544-2555.
47. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427-434.
48. Kharfan-Dabaja MA, Patel SA, Osunkoya AO, et al.: Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: Incidence and feasibility of immunohistochemical staining. Clin Lab Haematol 2006, 28: 254-258.
49. Kuzu I, Beksac M, Arat M, et al.: Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): Therapy induced changes and effects on survival. Leuk Lymphoma 2004, 45: 1185-1190.
50. Perez-Atayde AR, Sallan SE, Tedrow U, et al.: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997, 150: 815-821.
51. Fiedler W, Serve H, Dohner H, et al.: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105: 986-993.
52. Reichert F, Barak V, Tarshis M, et al.: Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies. Eur J Haematol 2005, 75: 41-46.
53. Roboz GJ, Giles FJ, List AF, et al.: Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006, 20: 952-957.
54. Thomas DA, Estey E, Giles FJ, et al.: Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003, 123: 436-441.
55. Andersson MK, Aman P: Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell Int 2008, 8: 1.
56. Kim ES, Serur A, Huang J, et al.: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002, 99: 11399-11404.
57. Lai A, Filka E, McGibbon B, et al.: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71: 1372-1380.
58. McCrudden KW, Hopkins B, Frischer J, et al.: Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003, 38: 308-314.
59. Rowe DH, Huang J, Kayton ML, et al.: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000, 35: 30-32; discussion 32-33.
60. Maris JM, Courtright J, Houghton PJ, et al.: Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 51: 42-48.
61. Maris JM, Courtright J, Houghton PJ, et al.: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50: 581-587.
62. Beaudry P, Nilsson M, Rioth M, et al.: Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 2008, 7: 418-424.
63. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006, 124: 471.
64. Allen GW, Saba C, Armstrong EA, et al.: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007, 67: 1155-1162.
65. Dunn SE, Hardman RA, Kari FW, Barrett JC: Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997, 57: 2687-2693.
66. MacEwen EG, Pastor J, Kutzke J, et al.: IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004, 92: 77-91.
67. Scotlandi K, Benini S, Sarti M, et al.: Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 1996, 56: 4570-4574.
68. Wang W, Kumar P, Wang W, et al.: Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998, 58: 4426-4433.
69. Werner H, Idelman G, Rubinstein M, et al.: A novel EWSWT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett 2007, 247: 84-90.
70. Werner H, Shen-Orr Z, Rauscher FJ 3rd, et al.: Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995, 15: 3516-3522.
71. Zumkeller W, Westphal M: The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001, 54: 227-229.
72. Benini S, Manara MC, Baldini N, et al.: Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001, 7: 1790-1797.
73. Martins AS, Mackintosh C, Martin DH, et al.: Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006, 12: 3532-3540.
74. Doepfner KT, Spertini O, Arcaro A: Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007, 21: 1921-1930.
75. Vorwerk P, Wex H, Hohmann B, et al.: Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol Pathol 2002, 55: 40-45.
76. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64: 7099-7109.
77. Normanno N, Bianco C, Strizzi L, et al.: The ErbB receptors and their ligands in cancer: An overview. Curr Drug Targets 2005, 6: 243-257.
78. Boissel N, Leroy H, Brethon B, et al.: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20: 965-970.
79. Lu D, Nounou R, Beran M, et al.: The prognostic signifi-cance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003, 97: 441-449.
80. Chen Y, Takita J, Hiwatari M, et al.: Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006, 45: 583-591.
81. Weiss B, Bollag G, Shannon K: Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999, 89: 14-22.
82. Emanuel PD, Snyder RC, Wiley T, et al.: Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000, 95: 639-645.
83. Fenaux P, Raza A, Mufti GJ, et al.: A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 2007, 109: 4158-4163.
84. Harousseau JL, Lancet JE, Reiffers J, et al.: A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007, 109: 5151-5156.
85. Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 2001, 97: 3361-3369.
86. Jeha S, Gandhi V, Chan KW, et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103: 784-789.
87. Robak T, Lech-Maranda E, Korycka A, Robak E: Purine nucleoside analogs as immunosuppressive and antineoplastic agents: Mechanism of action and clinical activity. Curr Med Chem 2006, 13: 3165-3189.
88. Bantia S, Ananth SL, Parker CD, et al.: Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 2003, 3: 879-887.
89. Cohen MH, JoNnson JR, Massie T, et al.: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006, 12: 5329-5335.
90. Furman RR, Gore L, Ravandi F, Hoelzer D: Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: Results of a phase II study (interim report). ASH Annual Meeting Abstracts 2006, 108: 1851.
91. Ritchie E, Gore L, Roboz G, et al.: Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. In 48th Annual Meeting of the American Society of Hematology. Orlando, Fl: 2006.
92. Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004, 22: 304-311.
93. Cusack JC Jr, Liu R, Houston M, et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61: 3535-3540.
94. Cortes J, Thomas D, Koller C, et al.: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10: 3371-3376.
95. Brignole C, Marimpietri D, Pastorino F, et al.: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98: 1142-1157.
96. Khan T, Stauffer JK, Williams R, et al.: Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 2006, 176: 6302-6312.
97. Soldatenkov VA, Dritschilo A: Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 1997, 57: 3881-3885.
98. Yan XB, Yang DS, Gao X, et al.: Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int 2007, 31: 1136-1143.
99. Houghton PJ, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50: 37-45.
100. Blaney SM, Bernstein M, Neville K, et al.: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group study (ADVL0015). J Clin Oncol 2004, 22: 4804-4809.
101. Horton TM, Pati D, Plon SE, et al.: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study. Clin Cancer Res 2007, 13: 1516-1522.
102. Chauhan D, Catley L, Li G, et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8: 407-419.
103. Chauhan D, Singh A, Brahmandam M, et al.: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111: 1654-1664.
104. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19: 6680-6686.
105. Bjornsti MAA Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4: 335-348.
106. Guba M, von Breitenbuch P, Steinbauer M, et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002, 8: 128-135.
107. Brown VI, Fang J, Alcorn K, et al.: Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 2003, 100: 15113-15118.
108. Teachey DT, Obzut DA, Cooperman J, et al.: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006, 107: 1149-1155.
109. Geoerger B, Kerr K, Tang CB, et al.: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001, 61: 1527-1532.
110. Johnsen JI, Segerstrom L, Orrego A, et al.: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008, 27: 2910-2922.
111. Wan X, Mendoza A, Khanna C, Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005, 65: 2406-2411.
112. Wan X, Shen N, Mendoza A, et al.: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006, 8: 394-401.
113. Houghton PJ, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50: 799-805.
114. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26: 5541-5552.
115. Banelli B, Di Vinci A, Gelvi I, et al.: DNA methylation in neuroblastic tumors. Cancer Lett 2005, 228: 37-41.
116. Obana K, Yang HW, Piao HY, et al.: Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 2003, 23: 1151-1157.
117. Park YB, Park MJ, Kimura K, et al.: Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002, 133: 105-111.
118. Hamann PR, Hinman LM, Hollander I, et al.: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002, 13: 47-58.
119. Gudowius S, Recker K, Laws HJ, et al.: Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatr 2006, 218: 327-333.
120. Mansfield E, Amlot P, Pastan I, FitzGerald DJ: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 1997, 90: 2020-2026.
121. Carnahan J, Stein R, Qu Z, et al.: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007, 44: 1331-1341.
122. Carnahan J, Wang P, Kendall R, et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 2003, 9: 3982S-3990S.
123. Yao Q, Weigel B, Kersey J: Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007, 13: 1591-1600.
124. Schulte TW, Blagosklonny MV, Romanova L, et al.: Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996, 16: 5839-5845.
125. Whitesell L, Mimnaugh EG, De Costa B, et al.: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91: 8324-8328.
126. George P, Bali P, Cohen P, et al.: Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004, 64: 3645-3652.
127. Mesa RA, Loegering D, Powell HL, et al.: Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005, 106: 318-327.
128. Bagatell R, Beliakoff J, David CL, et al.: Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005, 113: 179-188.
129. Garcia-Morales P, Carrasco-Garcia E, Ruiz-Rico P, et al.: Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene 2007, 26: 7185-7193.
130. Kang J, Kamal A, Burrows FJ, et al.: Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 2006, 26: 1903-1908.
131. Bagatell R, Gore L, Egorin MJ, et al.: Phase I pharmacokinetic and pharmacodynamic study of 17-Nallylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: A pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007, 13: 1783-1788.
132. Weigel BJ, Blaney SM, Reid JM, et al.: A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: A Children's Oncology Group study. Clin Cancer Res 2007, 13: 1789-1793.
133. Grabher C, von Boehmer H, Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006, 6: 347-359.
134. Artavanis-TCakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 1999, 284: 770-776.
135. Pahlman S, Stockhausen MT, Fredlund E, Axelson H: Notch signaling in neuroblastoma. Semin Cancer Biol 2004, 14: 365-373.
136. Baliko F, Bright T, Poon R, et al.: Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. Am J Pathol 2007, 170: 1686-1694.
137. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP: Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008, 14: 2962-2969.
138. Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306: 269-271.
139. Wong GT, Manfra D, Poulet FM, et al.: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004, 279: 12876-12882.
140. Breunig JJ, Silbereis J, Vaccarino FM, et al.: Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. Proc Natl Acad Sci U S A 2007, 104: 20558-20563.